ArticleThe Lancet. Haematology2017

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Sonali M Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.